Chr. Hansen Holding (CHR.CO) Stock Analysis & AI Equity Report
Chr. Hansen Holding (CHR.CO) overview
Chr. Hansen Holding (CHR.CO) stock analysis and AI equity research. For the latest completed financial year, 2023, Chr. Hansen Holding reported revenue of EUR 1,334m and operating profit of EUR 359m; the year-end share price was 449.40 DKK and market capitalisation was DKK 59,310m. Chr. Hansen Holding is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Chr. Hansen Holding's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-05. Data will be refreshed during report generation.
About Chr. Hansen Holding
Chr. Hansen Holding A/S develops microbial and fermentation-based biosolutions for food, nutrition, pharmaceutical and agricultural customers. Its portfolio includes cultures, enzymes, probiotics and natural colors used to improve taste, texture, shelf life, health benefits and production efficiency. In 2024, Chr. Hansen and Novozymes combined to form Novonesis.
Generate the Chr. Hansen Holding report
Chr. Hansen Holding is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Chr. Hansen Holding and represent the latest completed financial year (2023). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.